2,5-Dioxo-1-pyrrolidinyl 25-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-17,21,25-trioxo-4,7,10,13-tetraoxa-16,22-diazapentacosanoate

Catalog No. :
ACDFHT520
CAS No. :
1337920-28-1
Molecular Formula :
C38H46N4O11
Molecular Weight :
734.80

IUPAC Name:-

2,5-Dioxo-1-pyrrolidinyl 25-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-17,21,25-trioxo-4,7,10,13-tetraoxa-16,22-diazapentacosanoate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,5-Dioxo-1-pyrrolidinyl 25-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-17,21,25-trioxo-4,7,10,13-tetraoxa-16,22-diazapentacosanoate
Molecular FormulaC38H46N4O11
Molecular Weight734.80
SMILESO=C(CCOCCOCCOCCOCCNC(CCCC(NCCC(N1C2=C(C#CC3=C(C1)C=CC=C3)C=CC=C2)=O)=O)=O)ON4C(CCC4=O)=O
InChI KeyDUGJQIMCFRYXAT-UHFFFAOYSA-N
Synonym4,7,10,13-Tetraoxa-16,22-diazapentacosanoic acid, 25-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-17,21,25-trioxo-, 2,5-dioxo-1-pyrrolidinyl ester
CAS No.1337920-28-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACDFHT520 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACDRJA672 route compound structure diagram
    ACDRJA6721337920-25-8 In Stock
  4. Then
  5. ACDFHT520 route product structure diagram
    ACDFHT5201337920-28-1
Inquiry

2. ACDFHT520 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGKNT130 route compound structure diagram
    ACGKNT1301255942-06-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDFHT520 route product structure diagram
    ACDFHT5201337920-28-1
Inquiry

Comments (0)